Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Meeting Calendar
  3. Past Meetings
  4. ESMO Sarcoma and Rare Cancers Congress 2024
  5. Satellite Symposia Webcasts

Deciphera Pharmaceuticals - Progress through tyrosine kinase inhibitor (TKI) therapies in rare sarcoma subtypes

Unmet need and changing treatment landscape for TGCT patients

Date

14 Mar 2024

Session

Deciphera Pharmaceuticals - Progress through tyrosine kinase inhibitor (TKI) therapies in rare sarcoma subtypes

Presenters

Hans Gelderblom

Authors

H. Gelderblom

Author affiliations

  • Medical Oncology Dept, LUMC - Leids Universitair Medisch Centrum, 2300 RC - Leiden/NL

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and introduction

Presenter: Peter Reichardt

Session: Deciphera Pharmaceuticals - Progress through tyrosine kinase inhibitor (TKI) therapies in rare sarcoma subtypes

Resources:

Webcast

Q&A

Session: Deciphera Pharmaceuticals - Progress through tyrosine kinase inhibitor (TKI) therapies in rare sarcoma subtypes

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.